Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma, Renal Cell Carcinoma
Conditions
Brief summary
Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers. Participants will have cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable) or relapsed or refractory to prior treatments. This Phase 1/2 study will have three parts. The dose escalation part of the study will find out how much and how frequently GEN1160 should be given to participants. The expansion Part A and expansion Part B will use the dose and schedule found in the dose escalation part to find out how safe GEN1160 is and if it works to treat the diseases under study. The diseases under study will be Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC) and Non-Hodgkin Lymphoma (NHL) in Escalation and diffuse large B-cell lymphoma (DLBCL) in expansion Part A and Part B.
Detailed description
This is a Phase 1/2 study of GEN1160, a CD70 targeted antibody-drug conjugate, to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1160 in participants with selected locally advanced /or metastatic solid and hematologic malignancies, including RCC, NPC and NHL. This study consists of 3 parts, Dose Escalation, Expansion Part A and Expansion Part B. Dose escalation may evaluate up to 5 dose levels of GEN1160 on Day 1 of a 21 day cycle by intravenous (IV) infusion. Expansion will be initiated at a dose level based on a comprehensive analysis of safety, tolerability, clinical PK, pharmacodynamics (PD) and activity data from the dose escalation. Expansion will be conducted in 1 cohort of up to 10 participants (expansion Part A) and 2 further cohorts (expansion Part B), each with up to 25 participants per cohort. Participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, initiation of non-GEN1160 anticancer therapy, participant noncompliance, pregnancy, or death.
Interventions
BIOLOGICALGEN1160
IV infusion of GEN1160
Sponsors
Genmab
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Dose Escalation: Key Inclusion Criteria: * All participants must have pathologically confirmed diagnosis of one of the following tumor types: * Metastatic RCC, including clear cell renal cell carcinoma (ccRCC) or papillary RCC * Metastatic or relapsed Epstein Barr virus (EBV)-associated NPC not amenable to further local therapies (EBV association may have been determined by testing on tumor tissue or peripheral blood) * Advanced (Stage III or IV) NHL, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) requiring systemic therapy, and mantle cell lymphoma (MCL) * Participants must have relapsed or refractory disease following prior systemic therapies known to confer clinical benefit. At minimum, participants should have received the following therapies (unless deemed ineligible, refused by the participant, or not available in the region): * Participants with RCC must have received a minimum of one prior treatment regimen, and have received a tyrosine kinase inhibitor (TKI) and a programmed cell death (ligand) (\[PD\[L)\])-1 inhibitor * Participants with EBV-associated NPC must have received a minimum of one prior treatment regimen, which must include a platinum-based chemotherapy regimen * Participants with DLBCL must have received a minimum of 2 prior treatment regimens, including a multi-agent chemoimmunotherapy regimen given with curative intent (eg, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-CHOP\]), and participants must have received intensive salvage chemotherapy with hematopoietic stem cell transplant (HSCT) if considered eligible by the investigator * Participants with FL must have received a minimum of 2 prior treatment regimens, which must include a multi-agent chemoimmunotherapy regimen including an anti-CD20 agent * Participants with mantle cell lymphoma (MCL) must have received a minimum of 2 prior treatment regimens, which must include a multi-agent chemoimmunotherapy regimen including an anti-CD20 agent * Measurable disease at baseline: * Participants with RCC and NPC must have measurable disease as defined per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 (Eisenhauer et al., 2009) * Participants with NHL must have measurable disease as defined by the Lugano Classification (Cheson et al., 2014) * Participants must be willing to provide a pre-treatment tumor specimen (archival or new tissue biopsy samples). If a new tissue biopsy is required, procedures more invasive than a core biopsy or significant risk procedures for which the procedure-associated absolute risk of mortality or major morbidity in the participant's clinical setting and specific institution is 2% or higher, should not be utilized. Dose Escalation Key
Exclusion criteria
* Prior treatment with anti-CD70 directed therapy * Prior therapy with an antibody-drug conjugate (ADC) with a topoisomerase 1 inhibitor payload * Prior allogeneic hematopoietic stem cell transplant (HSCT). Participants with prior autologous HSCT must have completed the procedure at least 100 days prior to the first dose of study drug. * Known active central nervous system metastases, including carcinomatous meningitis. Participants with brain metastases may participate provided the metastases have been treated and are stable for at least 4 weeks prior to the first dose of study drug, they have no new or enlarging brain metastases and have discontinued corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug. Participants with a history of brain metastases, suspected new brain metastases, or a diagnosis of RCC should have a magnetic resonance imaging (MRI) of the brain at screening. Expansion: Key Inclusion Criteria: * Has pathological diagnosis of DLBCL, not otherwise specified (NOS) as defined by the World Health Organization (WHO) 2016 classification including both de novo or histologically transformed. * Has relapsed or refractory disease with no available standard therapy or is not a candidate for available standard therapy, and for whom, in the opinion of the investigator, experimental therapy with GEN1160 may be beneficial. Participant must have received at least 2 systemic treatment regimens including CD20-containing chemoimmunotherapy. * Has measurable disease according to the 2014 Lugano criteria (Cheson et al., 2014): * A fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan demonstrating positive lesion compatible with computed tomography (CT)- or MRI-defined anatomical tumor sites; AND * A CT scan (or MRI) with involvement of ≥ 1 measurable nodal lesion (long axis \> 1.5 centimeters (cm) and short axis \> 1.0 cm) and/or ≥ 1 measurable extranodal lesion (long axis \> 1.0 cm). * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Has a fresh biopsy (if clinically feasible and not considered as a high-risk procedure) or an archival tumor biopsy and submit to the central laboratory for CD70 assay * Has acceptable laboratory test results per protocol Expansion: Key
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose Escalation: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) | Up to approximately 1 year |
| Dose Escalation: Number of Participants with Dose Limiting Toxicities (DLTs) | 28 days |
| Expansion Parts A and B: Objective Response Rate (ORR) | Up to approximately 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Dose Escalation: ORR | Up to approximately 1 year |
| Dose Escalation: Disease Control Rate (DCR) | Up to approximately 1 year |
| Dose Escalation and Expansion Parts A and B: Progression-free Survival (PFS) | Up to approximately 18 months |
| Dose Escalation and Expansion Parts A and B: Duration of Objective Response (DOR) | Up to approximately 1 year |
| Dose Escalation and Expansion Parts A and B: Peak Plasma Concentration (Cmax) of GEN1160-related Analytes | Up to approximately 1 year |
| Dose Escalation and Expansion Parts A and B: Time to Maximum Concentration (Tmax) of GEN1160-related Analytes | Up to approximately 1 year |
| Dose Escalation and Expansion Parts A and B: Area Under the Curve up to the Last Quantifiable Time-point (AUC0-last) of GEN1160-related Analytes | Up to approximately 1 year |
| Dose Escalation and Expansion Parts A and B: Number of Participants with Antidrug Antibodies (ADA) | Up to approximately 1 year |
| Expansion Parts A and B: Complete Response (CR) Rate | Up to approximately 1 year |
| Expansion Parts A and B: Overall Survival (OS) | Up to approximately 18 months |
| Expansion Parts A and B: Number of Participants with TEAEs | Up to approximately 1 year |
| Expansion Parts A and B: Number of Participants with Anti-GEN1160 Antibodies | Up to approximately 1 year |
| Expansion Parts A and B: Time-to response (TTR) | Up to approximately 1 year |
Countries
China, United States
Contacts
STUDY_DIRECTORStudy Official
Genmab
Outcome results
None listed